Recent studies indicated that the efficacy of anti-PD-1 antibodies was largely confined to patients with tumors that have robust baseline CD8+ T cell infiltrates [10], and the modified oncolytic herpes virus T-VEC could enhance the immunogenicity of melanomas for which baseline immune recognition was lacking or not robust [3]. Here, PDCD1 is linked to melanoma.